Drug intelligence / Profile preview

LY3522348

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY3522348 is a highly selective, orally bioavailable small molecule inhibitor that targets human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). It was developed to reduce the lipogenic effects of high fructose intake by inhibiting the enzyme responsible for fructose phosphorylation in the liver. This mechanism aims to decrease hepatic steatosis and fibrogenesis, making it a potential therapeutic candidate for metabolic diseases such as nonalcoholic steatohepatitis (NASH) and kidney disease. The drug has demonstrated robust pharmacodynamic responses in preclinical models of fructose metabolism and has advanced into clinical trials. LY3522348 was discovered and developed by Eli Lilly[1][2][4][5].

Other names: KHK-IN-3KHK-IN3KHK-IN 3compound 23compound23compound-23

Targets

KHK-C (Ketohexokinase C)

Beyond the preview

Go deeper on LY3522348.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3522348.

Explore the full profile